Fundraising FoxNurix Therapeutics
San Francisco, US · Founded 2009 · 7 known investors
Find your way into Nurix Therapeutics
310 people in our graph can introduce you to the Nurix Therapeutics team.
Sign up to see every warm intro you have to Nurix Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Nurix Therapeutics team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Nurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases. The company applies targeted protein degradation to overcome limitations of conventional therapeutic approaches.
Founders & leadership
Board
Investors · 7
How we know: Bain Capital Life Sciences's portfolio page · Not right? Tell us
How we know: Foresite Capital's portfolio page · Not right? Tell us
How we know: Sofinnova Ventures's portfolio page · Not right? Tell us
How we know: The Column Group's portfolio page · board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$139.4M disclosed across 3 rounds · 2013–2020
▶$120.2MraisedMar 2020 · 23 investors · OtherRule 506(b)
- Arthur SandsExecutive Officer, Director
- Lori KunkelDirector
- Julia GregoryDirector
- Jeff TongDirector
- Robert TjianDirector
- David LaceyDirector
- Christine RingExecutive Officer
- Hans van HouteExecutive Officer
- Leon ChenDirector
- Offering amount
- $120.2M
- Amount sold
- $120.2M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$17MraisedSep 2015 · 1 investors · OtherRule 506(b)
- David GoeddelDirector
- Mark GoldsmithDirector
- Arthur T. SandsExecutive Officer, Director
- Timothy KutzkeyExecutive Officer, Director
- Offering amount
- $17M
- Amount sold
- $17M
- First sale
- Sep 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.1MraisedJan 2014 · 2 investors · OtherRule 506(b)
- Mark GoldsmithExecutive Officer, Director
- Timothy KutzkeyExecutive Officer, Director
- David GoeddelDirector
- Offering amount
- $25.1M
- Amount sold
- $2.1M
- First sale
- Dec 2013
- Incorporated
- Corporation, Delaware, 2009
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Nurix Therapeutics do?
- Nurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases. The company applies targeted protein degradation to overcome limitations of conventional therapeutic approaches.
- Who are Nurix Therapeutics's investors?
- Nurix Therapeutics's investors include Bain Capital Life Sciences, EcoR1 Capital, Foresite Capital, Sofinnova Ventures, The Column Group, Wellington Management, Third Rock Ventures.
- How much funding has Nurix Therapeutics raised?
- Nurix Therapeutics has disclosed $139.4M raised across 3 rounds.
- Where is Nurix Therapeutics headquartered?
- Nurix Therapeutics is headquartered in San Francisco, US.